A drug that may speed platelet recovery after stem cell transplants in kids
NCT ID NCT07003256
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This study explores whether romiplostim, a drug that stimulates platelet production, can safely and effectively help platelet recovery in children with thalassemia who receive a half-matched stem cell transplant. Researchers will track how quickly platelet levels rise, how many platelet transfusions are needed, and any side effects. The study involves 16 children aged 2 to 17 who have already received romiplostim as part of their routine care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- romiplostim (Nplate), a drug to boost platelet production
- What this could lead to
- If successful, this could point toward a way to speed platelet recovery and reduce bleeding risk after stem cell transplants for children with thalassemia.
- What could go wrong
- This is a small, early observational study with only 16 participants, so results may not apply broadly. The drug may cause side effects like thrombosis or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
16 people
The number who actually took part.
- Started
-
Sep 2024
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Children aged 2 - 17 years old who were diagnosed with severe thalassemia at Haikou People's Hospital and received haploidentical hematopoietic stem cell transplantation.
- Ages
-
2 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * After undergoing Mediterranean gene testing, reviewing the history of blood transfusions, and conducting a blood routine examination, the patient was diagnosed with severe thalassemia. * Children aged 2 - 17 years old. * Agree to the haploidentical transplantation, and the team has evaluated that there are no transplantation contraindications. Exclusion Criteria: * There is a fully matched donor, and transplantation with a half - matched donor is not agreed. * For donors and recipients, the transaminase is more than twice the normal value. * Donor specific antibody Greater than 5000, and after antibody treatment, it should not be lower than 3000. * Positive for hepatitis B DNA. * There is an active infection. * After evaluation by the transplantation team, there are contraindications for transplantation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thalassemia in children are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Haikou, Hainan, 570208, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.